Overall, our study demonstrated the oncogenic role of GBE1/c-Myc axis in PC and WTAP/IGF2BP3-mediated upregulation of GBE1 via m6A modification, which providing a promising therapeutic target for PC treatment. Here, IGF2BP3 is linked to pachyonychia congenita.